Malin in valuation fall amid Poseida sale, EU150 million return
Malin Corp PLC on Wednesday reported a valuation decline over the first half of 2025, but hailed the sale of its Poseida Therapeutics Inc stake as a ‘very significant milestone’.
Roche Holding AG in January sealed the sale of clinical-stage biopharmaceutical company Poseida for around $1.5 billion.
Life sciences investment firm Malin, which held around 12% of Poseida, said at the time that the deal would generate it proceeds of around $106.5 million. An additional $47.3 million could come from contingent upon the achievement of specified milestones.
‘Beginning 2025 with the sale of Poseida represented a very significant milestone for Malin in our continuing strategy to deliver maximum value to shareholders,’ Malin Chief Executive Officer Fiona Dunlevy said. ‘We were delighted that through the sale of Poseida, together with the divestment of Malin’s interest in CG Oncology in mid-2024, we were able to deliver a significant capital return to shareholders of €150 million in March 2025’.
Malin said its estimated intrinsic equity value per share at the June 30 half-year end was €9.52, fading from €10.36 in December.
The firm said: ‘The net decrease in Malin’s intrinsic equity value over the period is primarily attributable to the divestment of Poseida in January 2025, the subsequent return of capital of €150 million in March 2025 and to a downward revision to the estimated valuation of Malin’s interest in Viamet.’
Malin shares were untraded in Dublin on Wednesday afternoon, last quoted at €8.00.
Copyright 2025 Alliance News Ltd. All Rights Reserved.